| GILD |
Report |
Yeztugo Revenue (Q2 2026) |
BEAT |
pred ~$245M vs. cons $227M |
MEDIUM |
| GILD |
Report |
HIV Total Revenue (Q2 2026) |
BEAT |
pred ~$5,480M vs. cons $5,396M |
MEDIUM |
| GILD |
Report |
Trodelvy Revenue (Q2 2026) |
MISS |
pred ~$415M vs. cons $425M |
MEDIUM |
| GILD |
Guide |
Total Product Sales (FY2026) |
BETTER |
guide ~$30.5-30.8B vs. cons $30.42B |
MEDIUM |
| GILD |
Guide |
Yeztugo (FY2026) |
BETTER |
guide ~$1.05-1.10B vs. cons $1.050B |
MEDIUM |
| GILD |
Guide |
HIV Total Sales Growth (FY2026) |
UNCHANGED |
guide ~8% YoY vs. cons ~8% YoY |
HIGH |
| GILD |
Guide |
Veklury (FY2026) |
UNCHANGED |
guide ~$600M vs. cons $582M |
HIGH |
| GILD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.5% |
— |
MEDIUM |
| GILD |
Return |
5-day cumulative residual |
+2.5% (FADE) |
FADE — Archetype A low-bar quarters historically fade 5-day as sell-side digests modest raise; Trodelvy miss and slightly negative HIV revision trend limit follow-through |
MEDIUM |